Providers

Patients living with myasthenia gravis in Australia were surveyed their demographic information, clinical features of the autoimmune disease, adverse effects from treatment, and quality of life. Outcomes were compared against 2011 data from Australia and 2019 data from the United States.

A mandatory nationwide transition from reference adalimumab to a biosimilar was implemented in New Zealand.

Incident reporting systems, which are often computer based and require no in-person interactions, can enable health care staff who perceive low psychological safety to speak up.

A case report highlights the benefits of applying patient-tailored therapies to mitigate the effects of neuromuscular immune-related adverse events and improve patient outcomes.

Guru Sonpavde, MD, medical director of genitourinary oncology at the AdventHealth Cancer Institute, discussed the promising findings of the CheckMate 901 trial exploring the potential of nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma.

A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.

A cross-sectional study suggests that spinal muscular atrophy (SMA) can contribute to cognitive impairment.

In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.

A cross-sectional study revealed that neuroinflammation is linked to irritability, among other neuropsychiatric symptoms, in patients with Alzheimer disease (AD).

Data are scarce on the impact that breast cancer among mothers has on their children and their emotional development due to parenting stress and maternal depression.

A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.

Early CT screening leads to a 20-year lung cancer survival rate of 81%.

Managing toxicities for patients on immunotherapy requires collaboration with specialists to manage specific organ toxicities and moving beyond steroids, according to a presentation at the ESMO Congress 2023.

A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the impacts of immunotherapy on outcomes for certain patients with non–small cell lung cancer.

A retrospective analysis reveals that pregnant patients with autoimmune skin diseases have higher risks for adverse pregnancy outcomes.

A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.

Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.

In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.

Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.

The recent availability of 3 FDA-approved treatments for patients with spinal muscular atrophy (SMA) has dramatically altered patient outcomes and provided a wealth of new avenues for SMA research.

In a single-center, retrospective analysis, echocardiography demonstrated low sensitivity but high specificity for diagnosing pulmonary hypertension (PH) in advanced chronic obstructive pulmonary disease (COPD).

Patients with diverse skin types can experience diagnostic delays, access to care issues, and quality-of-life burdens that a navigator program may be able to help alleviate.

To stress the importance of considering pulmonary complications in sickle cell disease (SCD), researchers compiled an overview on the state of research and available treatment options for patients with SCD associated with pulmonary hypertension.

The study also identified similar 12-month outcomes between torsemide and furosemide regardless of heart failure (HF) type.